InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by Edick Paul R, Chief Executive Officer. Director active across 2 companies, notably Xeris Pharmaceuticals INC. Cumulatively, 11 reports have been recorded. Total volume traded: €939k. The latest transaction was filed on 12 May 2022 — Acquisition. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations11 total
€135,246100,000 shares@ €1.35250.010% mcap14.4% of flow
Common Stock
SEC:0001867096-22-000067:0·
Ideal exit: 6 Feb 2023 (T+270)
0600,000 shares0
Common Stock
SEC:0001867096-22-000007:0·
0600,000 shares0
Common Stock
SEC:0001867096-22-000007·
€39,91020,000 shares@ €1.99550.0031% mcap9.9% of flow
Common Stock
SEC:0001867096-21-000080·
Ideal exit: 12 Aug 2022 (T+270)
€39,91020,000 shares@ €1.99550.0031% mcap4.3% of flow
Common Stock
SEC:0001867096-21-000080:0·
Ideal exit: 12 Aug 2022 (T+270)
€361,973200,000 shares@ €1.80990.028% mcap90.1% of flow
Common Stock
SEC:0001867096-21-000076·
Ideal exit: 8 Aug 2022 (T+270)
€361,973200,000 shares@ €1.80990.028% mcap38.5% of flow
Common Stock
SEC:0001867096-21-000076:0·
Ideal exit: 8 Aug 2022 (T+270)
197,231 shares
Common Stock
SEC:0000899243-21-039254·
197,231 shares
Common Stock
SEC:0000899243-21-039335·
197,231 shares
Common Stock
SEC:0000899243-21-039254:0·
197,231 shares
Common Stock
SEC:0000899243-21-039335:0·
11 of 11 declarations
About Edick Paul R
Paul R. Edick is the Chief Executive Officer of Xeris Pharmaceuticals Inc and Xeris Biopharma Holdings, Inc. He leads the strategic operations of these biopharmaceutical companies, focusing on innovation in medical treatments. His leadership is essential for advancing the research and development missions.
